UFT与丝裂霉素C辅助化疗用于晚期结直肠癌的多中心随机前瞻性研究。
Multicenter randomized prospective study of adjuvant chemotherapy with UFT and mitomycin C in advanced colorectal cancer.
作者信息
Nakagoe T, Ishikawa H, Sawai T, Tuji T, Ayabe H, Eida K, Nogawa T, Nakamura Y, Kunisaki T, Tobinaga K, Furukawa M, Ino M
机构信息
First Department of Surgery, Nagasaki University School of Medicine, Japan.
出版信息
Anticancer Res. 2000 Mar-Apr;20(2B):1069-75.
BACKGROUND
A randomized prospective trial was performed to determine the efficacy of preoperative and postoperative adjuvant oral UFT, administered with mitomycin C (MMC) after resection for advanced colorectal cancer.
MATERIALS AND METHODS
A total of 126 patients were entered in the study. The patients received UFT (400 mg daily) administered orally for seven days prior to surgery and were randomly assigned to two groups immediately following surgery. Group A received MMC postoperatively; Group B received the same regimen as Group A, plus administration of UFT orally at a dose of 400 mg daily for one year.
RESULTS
The survival results revealed no significant difference between groups A and B. In patients with nuclear DNA aneuploid tumors, the hematogenous recurrence rate after curative surgery was lower in Group B than in Group A (P = 0.0656).
CONCLUSIONS
Preoperative and postoperative adjuvant oral UFT, administered with MMC after curative resection, may be effective in preventing hematogenous recurrence in colorectal cancer patients with nuclear DNA aneuploidy tumors.
背景
进行了一项随机前瞻性试验，以确定术前和术后辅助口服优福定（UFT）联合丝裂霉素C（MMC）在晚期结直肠癌切除术后的疗效。
材料与方法
共有126例患者纳入本研究。患者在手术前7天口服UFT（每日400mg），术后立即随机分为两组。A组术后接受MMC治疗；B组接受与A组相同的治疗方案，外加术后口服UFT，每日剂量为400mg，持续一年。
结果
生存结果显示A组和B组之间无显著差异。在核DNA非整倍体肿瘤患者中，B组根治性手术后的血行复发率低于A组（P = 0.0656）。
结论
根治性切除术后，术前和术后辅助口服UFT联合MMC可能对预防核DNA非整倍体肿瘤的结直肠癌患者血行复发有效。
Zotero 插件